Upcoming Earnings: Q4 '26
Estimated EPS
$2.89
Estimated Rev
$1.46B
$RMD Q3 '26 Earnings Results & Recap • Reported GAAP EPS of $2.74 up 10.04% YoY • Reported revenue of $1.43B up 10.81% YoY • As Resmed advances through the remainder of fiscal year 2026, the company remains focused on expanding access to care globally, scaling digital health capabilities, and delivering further strong, profitable growth.
Generated by Stocktwits using AI and company-reported earnings data for Q4 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q4 '26 | $2.89 | -- | -- | N/A |
Q3 '26 | $2.80 | $2.86 | 2.32% | BEAT |
Q2 '26 | $2.74 | $2.81 | 2.73% | BEAT |
Q1 '26 | $2.52 | $2.55 | 1.32% | BEAT |
Q4 '25 | $2.49 | $2.55 | 2.32% | BEAT |
